Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China. (linkinghub.elsevier.com)

Authors: Xu CR … Wu YL Journal: The Lancet Published: 2026-10-26 DOI: https://doi.org/10.1016/S0140-6736(26)01899-4